Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality

Joseph M. Unger; Hillary Stires; Laura A. Levit; Mark Stewart; Brittany Avin McKelvey; Beverly Canin; Emily Dressler; Keith Flaherty; Peter Fredette; Lee Jones; Peggy McCann; Therica Miller; Adedayo A. Onitilo; Fran Palmieri; Timil Patel; Rocio Paul; Gary L. Smith; Suanna S. Bruinooge; Elizabeth Garrett-Mayer; Xiudong Jennifer Lei; Ajjai Alva; Caroline Schenkel

Journal ArticleOPEN ACCESS

Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality

Unger J
Stires H
Levit L
et al.

JCO Oncology Practice (2023) 19(10) 907-916

DOI: 10.1200/op.23.00185

5Citations

10Readers

Get full text

Abstract

ASCO-Friends study: sponsors say COVID-19–era trial flexibilities had minimal impact on treatment trial data integrity.

Cite

CITATION STYLE

APA

Unger, J. M., Stires, H., Levit, L. A., Stewart, M., McKelvey, B. A., Canin, B., … Schenkel, C. (2023). Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality. JCO Oncology Practice, 19(10), 907–916. https://doi.org/10.1200/op.23.00185

Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality

Abstract

Cite

Register to see more suggestions